A Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Active, not recruiting
• Trial end date: 2022-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment

• Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months

Exclusion Criteria:

• Current or anticipated enrollment in another investigational drug or device study

• Females who are pregnant, nursing, or planning a pregnancy during the study